Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Aug;36(8):1671–1676. doi: 10.1128/aac.36.8.1671

Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals.

D Girard 1, T D Gootz 1, P R McGuirk 1
PMCID: PMC192028  PMID: 1329625

Abstract

The pharmacokinetics of CP-74,667 (7-(8'-methyl-3',8'-diazabicyclo[3.2.1]oct-3'-yl)-1-cyclopropyl-6- fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid) were studied following oral or parenteral administration in mice, rats, rabbits, dogs, and cynomolgus monkeys. The mean peak levels of CP-74,667 in serum following a single oral dose of 20 mg/kg of body weight were similar in all species, with a range of 3.7 micrograms/ml in mice to 5.6 micrograms/ml in dogs. In contrast, elimination half-lives were species dependent, with mean values of 2.1, 1.8, 4.5, 7.8, and 13.1 h in mice, rats, rabbits, dogs, and monkeys, respectively. The oral bioavailability of CP-74,667 was 100% in dogs and monkeys, as determined by intravenous-oral crossover experiments. The maximum concentration of drug in serum and area under the concentration-time curve (AUC) of CP-74,667 in dogs were proportional to dose over the range of 5 to 40 mg/kg. Accumulation of drug in serum was observed following the administration of four once-a-day doses of 7.1 mg/kg in monkeys (mimicking a 500-mg human dose), with significant increases in half-life, maximum and minimum concentrations of drug in serum, and AUC. The good tissue penetration of CP-74,667 suggested by a volume of distribution in excess of 2 liters/kg in dogs and monkeys was confirmed by tissue distribution studies with the same species, which demonstrated tissue concentrations (except for those in brain tissue) greater than 1.45 times higher than corresponding levels in serum. The mean urinary recoveries of unchanged drug were 17.7% in rats, 7.8% in monkeys, and 4.9% in dogs. Metabolism studies in dogs, following intravenous dosing, indicated that renal excretion of CP-74,667-related materials accounted for 41.6% of the administered dose, while biliary recoveries accounted for 6.8%. The CP-74,667 N-oxide metabolite was the primary drug-related material eliminated via renal excretion (37.2% of dose). The pharmacokinetics of CP-74,667 describe a quinolone with complete oral absorption, linear pharmacokinetics, a long elimination half-life, and wide distribution into tissues.

Full text

PDF
1671

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barre J., Houin G., Tillement J. P. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. J Pharm Sci. 1984 Oct;73(10):1379–1382. doi: 10.1002/jps.2600731014. [DOI] [PubMed] [Google Scholar]
  2. Campoli-Richards D. M., Monk J. P., Price A., Benfield P., Todd P. A., Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988 Apr;35(4):373–447. doi: 10.2165/00003495-198835040-00003. [DOI] [PubMed] [Google Scholar]
  3. Chu D. T., Fernandes P. B. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother. 1989 Feb;33(2):131–135. doi: 10.1128/aac.33.2.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gilfillan E. C., Pelak B. A., Bland J. A., Malatesta P. F., Gadebusch H. H. Pharmacokinetic studies of norfloxacin in laboratory animals. Chemotherapy. 1984;30(5):288–296. doi: 10.1159/000238283. [DOI] [PubMed] [Google Scholar]
  5. Huttunen M., Kunnas K., Saloranta P. Enoxacin treatment of urinary tract infections in elderly patients. J Antimicrob Chemother. 1988 Feb;21 (Suppl B):105–111. doi: 10.1093/jac/21.suppl_b.105. [DOI] [PubMed] [Google Scholar]
  6. Joos B., Ledergerber B., Flepp M., Bettex J. D., Lüthy R., Siegenthaler W. Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother. 1985 Mar;27(3):353–356. doi: 10.1128/aac.27.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kusajima H., Ishikawa N., Machida M., Uchida H., Irikura T. Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys. Antimicrob Agents Chemother. 1986 Aug;30(2):304–309. doi: 10.1128/aac.30.2.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lode H., Höffken G., Prinzing C., Glatzel P., Wiley R., Olschewski P., Sievers B., Reimnitz D., Borner K., Koeppe P. Comparative pharmacokinetics of new quinolones. Drugs. 1987;34 (Suppl 1):21–25. doi: 10.2165/00003495-198700341-00006. [DOI] [PubMed] [Google Scholar]
  9. Monk J. P., Campoli-Richards D. M. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1987 Apr;33(4):346–391. doi: 10.2165/00003495-198733040-00003. [DOI] [PubMed] [Google Scholar]
  10. Montay G., Goueffon Y., Roquet F. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother. 1984 Apr;25(4):463–472. doi: 10.1128/aac.25.4.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nakamura S., Kurobe N., Kashimoto S., Ohue T., Takase Y., Shimizu M. Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother. 1983 Jul;24(1):54–60. doi: 10.1128/aac.24.1.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nakamura S., Kurobe N., Ohue T., Hashimoto M., Shimizu M. Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother. 1990 Jan;34(1):89–93. doi: 10.1128/aac.34.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nix D. E., De Vito J. M., Schentag J. J. Liquid-chromatographic determination of ciprofloxacin in serum and urine. Clin Chem. 1985 May;31(5):684–686. [PubMed] [Google Scholar]
  14. Panneton A. C., Bergeron M. G., LeBel M. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. Antimicrob Agents Chemother. 1988 Oct;32(10):1515–1520. doi: 10.1128/aac.32.10.1515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Plaisance K. I., Drusano G. L., Forrest A., Bustamante C. I., Standiford H. C. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1987 Jun;31(6):956–958. doi: 10.1128/aac.31.6.956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rohwedder R., Bergan T., Thorsteinsson S. B., Scholl H. Transintestinal elimination of ciprofloxacin. Chemotherapy. 1990;36(2):77–84. doi: 10.1159/000238751. [DOI] [PubMed] [Google Scholar]
  17. Stone J. W., Andrews J. M., Ashby J. P., Griggs D., Wise R. Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother. 1988 Oct;32(10):1508–1510. doi: 10.1128/aac.32.10.1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wartenberg K., Tonak J., Knapp W. Lung tissue concentrations of cefoperazone. Infection. 1983 Sep-Oct;11(5):280–282. doi: 10.1007/BF01641263. [DOI] [PubMed] [Google Scholar]
  19. Weidekamm E., Portmann R., Suter K., Partos C., Dell D., Lücker P. W. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrob Agents Chemother. 1987 Dec;31(12):1909–1914. doi: 10.1128/aac.31.12.1909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES